TW200738281A - Bazedoxifene acetate formulations - Google Patents

Bazedoxifene acetate formulations

Info

Publication number
TW200738281A
TW200738281A TW095130979A TW95130979A TW200738281A TW 200738281 A TW200738281 A TW 200738281A TW 095130979 A TW095130979 A TW 095130979A TW 95130979 A TW95130979 A TW 95130979A TW 200738281 A TW200738281 A TW 200738281A
Authority
TW
Taiwan
Prior art keywords
bazedoxifene acetate
acetate formulations
formulations
bazedoxifene
preparations
Prior art date
Application number
TW095130979A
Other languages
English (en)
Inventor
Syed M Shah
Christopher R Diorio
Eric C Ehrnsperger
Kadum A Ali
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200738281(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200738281A publication Critical patent/TW200738281A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
TW095130979A 2005-08-24 2006-08-23 Bazedoxifene acetate formulations TW200738281A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71076105P 2005-08-24 2005-08-24

Publications (1)

Publication Number Publication Date
TW200738281A true TW200738281A (en) 2007-10-16

Family

ID=37772333

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095130979A TW200738281A (en) 2005-08-24 2006-08-23 Bazedoxifene acetate formulations

Country Status (21)

Country Link
US (1) US7771744B2 (zh)
EP (1) EP1919456A2 (zh)
JP (2) JP2009506053A (zh)
KR (2) KR101584674B1 (zh)
CN (1) CN101304731B (zh)
AR (1) AR056471A1 (zh)
AU (1) AU2006283121A1 (zh)
BR (1) BRPI0615341A2 (zh)
CA (1) CA2620174A1 (zh)
CR (1) CR9746A (zh)
EC (1) ECSP088214A (zh)
GT (1) GT200600383A (zh)
IL (2) IL189648A (zh)
MX (1) MX2008002484A (zh)
NO (1) NO20080991L (zh)
PE (1) PE20070425A1 (zh)
RU (1) RU2417084C2 (zh)
SV (1) SV2008002825A (zh)
TW (1) TW200738281A (zh)
WO (1) WO2007024961A2 (zh)
ZA (1) ZA200801742B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR048534A1 (es) * 2004-04-08 2006-05-03 Wyeth Corp Formulaciones de acetato de bazedoxifeno
CA2620174A1 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof
MX2008012299A (es) * 2006-03-31 2008-11-18 Rubicon Res Private Ltd Tabletas de desintegracion oral.
WO2008079342A2 (en) * 2006-12-21 2008-07-03 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets
US20100016582A1 (en) * 2008-02-11 2010-01-21 Wyeth Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
EP2645994B1 (en) * 2010-11-30 2017-11-01 WisTa Laboratories Ltd. Formulations comprising methylthioninium chloride
EP2471770A1 (en) 2010-12-28 2012-07-04 Sandoz Ag Method of preparing polymorphic pure form A of bazedoxifene acetate
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
WO2013182169A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
CN103877581B (zh) * 2014-03-24 2016-03-02 江苏知原药业有限公司 一种性能优异的乙酸巴多昔芬缓释制剂
WO2018182205A1 (ko) * 2017-03-30 2018-10-04 한미약품 주식회사 바제독시펜 아세테이트를 함유하는 안정화된 약제학적 조성물
KR101940569B1 (ko) * 2017-05-24 2019-01-21 아주대학교산학협력단 바제독시펜 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물
CN112076163B (zh) * 2019-06-14 2023-06-20 四川科伦药物研究院有限公司 一种醋酸巴多昔芬片的药物组合物及其制备方法
CN111004165A (zh) * 2019-12-03 2020-04-14 南京正济医药研究有限公司 一种醋酸巴多昔芬晶型a的制备方法
CN112754999A (zh) * 2021-01-23 2021-05-07 郑州泰丰制药有限公司 一种醋酸巴多昔芬组合物及醋酸巴多昔芬薄膜衣片制备方法
CN113368075A (zh) * 2021-06-29 2021-09-10 郑州泰丰制药有限公司 一种醋酸巴多昔芬片及其制备方法
CA3229700A1 (en) * 2021-08-23 2023-03-02 Jan Brabek Treatment of covid-19

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686094A (en) * 1991-04-01 1997-11-11 Theratech, Inc. Controlled release formulations for the treatment of xerostomia
US6063403A (en) * 1995-06-22 2000-05-16 Akzo Nobel N.V. Compressed dry-granulation desogestrel tablets
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
CN1429222A (zh) 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
NZ537051A (en) * 2002-06-13 2007-11-30 Wyeth Corp Use of bazedoxifene in an extended dosage treatment regimen
SG149081A1 (en) 2004-01-13 2009-01-29 Wyeth Corp Treatment of aromatase inhibitor therapy-related osteoporosis
PE20060173A1 (es) * 2004-04-07 2006-04-12 Wyeth Corp Polimorfo cristalino de acetato de bazedoxifeno
KR20060135866A (ko) 2004-04-07 2006-12-29 와이어쓰 바제독시펜 아세테이트의 결정질 다형체
CN1938272A (zh) * 2004-04-07 2007-03-28 惠氏公司 巴泽多昔芬醋酸盐的结晶多晶型物
AR048534A1 (es) * 2004-04-08 2006-05-03 Wyeth Corp Formulaciones de acetato de bazedoxifeno
CA2620174A1 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof

Also Published As

Publication number Publication date
KR20080043853A (ko) 2008-05-19
JP2013209419A (ja) 2013-10-10
CN101304731A (zh) 2008-11-12
SV2008002825A (es) 2008-06-30
CR9746A (es) 2008-08-21
ZA200801742B (en) 2010-10-27
KR20140088917A (ko) 2014-07-11
RU2008107580A (ru) 2009-09-27
IL189648A (en) 2014-07-31
ECSP088214A (es) 2008-03-26
MX2008002484A (es) 2008-04-07
IL189648A0 (en) 2008-08-07
KR101584674B1 (ko) 2016-01-13
AR056471A1 (es) 2007-10-10
US20070048374A1 (en) 2007-03-01
US7771744B2 (en) 2010-08-10
RU2417084C2 (ru) 2011-04-27
PE20070425A1 (es) 2007-07-02
CN101304731B (zh) 2012-06-20
EP1919456A2 (en) 2008-05-14
BRPI0615341A2 (pt) 2011-05-17
WO2007024961A3 (en) 2007-06-28
AU2006283121A1 (en) 2007-03-01
JP2009506053A (ja) 2009-02-12
WO2007024961A2 (en) 2007-03-01
NO20080991L (no) 2008-05-15
IL233392A0 (en) 2014-08-31
IL233392A (en) 2017-02-28
CA2620174A1 (en) 2007-03-01
GT200600383A (es) 2007-03-29

Similar Documents

Publication Publication Date Title
TW200738281A (en) Bazedoxifene acetate formulations
TW200605863A (en) Bazedoxifene acetate formulations
SG151331A1 (en) Crystalline polymorph of a bazedoxifene acetate
UA86055C2 (ru) Кристаллическая форма в базедоксифена ацетата
MY153424A (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
TNSN07235A1 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
PH12015501484A1 (en) Heteroaryl compounds and uses thereof
JO3181B1 (ar) مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
MY148634A (en) Pyridazinone derivatives
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
UA83311C2 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2006004684A8 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2007072201A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
HK1133642A1 (en) Azaadamantane ester and carbamate derivatives and methods of use thereof
WO2008061108A3 (en) Phthalazine derivatives
WO2006031929A3 (en) Thiazolopyridine kinase inhibitors
UA85703C2 (en) Crystalline polymorph of bazedoxifene acetate
WO2006097809A3 (en) Novel tyrosine derivatives
PL1893597T3 (pl) Związki wspomagające działanie receptora AMPA
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
UA83142C2 (en) 3-aminocyclopentane carboxyamidine as modulators of chemokine receptors
UA92343C2 (en) Ampa receptor potentiators
RS20060104A (en) Delta 15-d-homosteroids having an androgenic effect